The overall goal of this program project is the translational development of radioisotopic carrier molecules and strategies to deliver systemic radiotherapy for lymphomas and adenocarcinomas such as prostate cancer. The first project focuses on developing novel synthetic high affinity ligands (SHALs) that will target the Lym-1 epitope of the beta subunit of HLA-DR, known to be present on malignant lymphocytes of almost all B cell types. The second project focuses on developing novel bispecific multivalent single chain variable fragment (scFv) MAbs to be used to pretarget prostate cancer and to be followed by a small multivalent DOTA chelator of 90y. Several different types of molecular modeling has been used in support of the Projects. Homology-based protein structure prediction was used to determine: 1) the structures of HLA-DR 10, and 2) scFv MAb targeting agents, as well as 3) the scFv raised against the 90y DOTA chelator. These predicted structures were used to help identify: 1) the Lym-1 MAb epitope for subsequent computational docking studies and 2) scFv binding sites against the DOTA chelator. Quantum chemical simulations and first principles molecular dynamics simulations were used to predict the effects of chemical modifications on the structure of the 90Y-DOTA and the DOTA-DOTA linker. Finally, classical molecular dynamics were used to assist in determining the binding orientations of ligands, the design of SHALS, the optimization of the DOTA-DOTA linker and PEGylated scFv scaffold. This core component provided the computational simulation expertise and facilities to achieve these aims. All simulations were performed using computer hardware and software already available to the group. We have significant computer resources within the biology program, and extensive computer time on much larger institutional computer facilities through internal grants. The investigators selected for this Core have extensive experience in the different molecular modeling methods to be employed.
| Schellinger, Joan G; Kudupudi, Avinash; Natarajan, Arutselvan et al. (2012) A general chemical synthesis platform for crosslinking multivalent single chain variable fragments. Org Biomol Chem 10:1521-6 |
| Saludes, Jonel P; Natarajan, Arutselvan; DeNardo, Sally J et al. (2010) The remarkable stability of chimeric, sialic acid-derived alpha/delta-peptides in human blood plasma. Chem Biol Drug Des 75:455-60 |
| Kumaresan, Pappanaicken R; Luo, Juntao; Lam, Kit S (2009) On-demand cleavable linkers for radioimmunotherapy. Methods Mol Biol 539:191-211 |
| DeNardo, G L; Mirick, G R; Hok, S et al. (2009) Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia. Int J Oncol 34:511-6 |
| Balhorn, Rod; Hok, Saphon; DeNardo, Sally et al. (2009) Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells. Mol Cancer 8:25 |
| Sulchek, Todd; Friddle, Raymond; Ratto, Timothy et al. (2009) Single-molecule approach to understanding multivalent binding kinetics. Ann N Y Acad Sci 1161:74-82 |
| DeNardo, Gerald L; DeNardo, Sally J; Balhorn, Rod (2008) Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies? Cancer Biother Radiopharm 23:383-97 |
| DeNardo, Gerald L; Natarajan, Arutselvan; Hok, Saphon et al. (2008) Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging. Cancer Biother Radiopharm 23:783-96 |
| Natarajan, Arutselvan; Xiong, Cheng-Yi; Gruettner, Cordula et al. (2008) Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. Cancer Biother Radiopharm 23:82-91 |
| Lehmann, Joerg; Natarajan, Arutselvan; Denardo, Gerald L et al. (2008) Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells. Cancer Biother Radiopharm 23:265-71 |
Showing the most recent 10 out of 187 publications
